Cargando…
Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer
Chemotherapy, in combination with immune checkpoint blockade (ICB) targeting to programmed death‐1 (PD‐1) or its ligand PD‐L1, is one of the first‐line treatments for patients with advanced non–small‐cell lung cancer (NSCLC). However, a large proportion of patients, especially those with PD‐L1 negat...
Autores principales: | Chen, Mei‐Chih, Hung, Meng‐Yu, Pan, Chih‐Ming, Huang, Shi‐Wei, Jan, Chia‐Ing, Li, Yu‐Hsuan, Chiu, Shao‐Chih, Cho, Der‐Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323078/ https://www.ncbi.nlm.nih.gov/pubmed/37017116 http://dx.doi.org/10.1111/cas.15806 |
Ejemplares similares
-
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020) -
Different immune contextures underlie tumor site‐specific responses to immune checkpoint blockade in esophageal cancer
por: Guo, Jhe‐Cyuan, et al.
Publicado: (2023) -
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
por: Huang, Shi‐Wei, et al.
Publicado: (2023) -
Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023) -
Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy
por: Zhang, Chi, et al.
Publicado: (2018)